Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
964.9 USD | -0.15% | -0.49% | +9.68% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 25 | Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.68% | 104B | |
+2.54% | 108B | |
+6.58% | 23.66B | |
-12.44% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.33% | 16.19B | |
+4.20% | 13.72B | |
+34.50% | 12.22B | |
-6.15% | 10.36B |
- Stock
- Equities
- Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022